Shares of drug developer Fractyl Health (GUTS.O) rise 1.4% to $1.49 premarket
Co says obesity gene therapy RJVA-002 showed ~30% weight loss in mice, in a preclinical trial
The therapy is designed to trigger the production of appetite-suppressing hormones, GLP-1 and GIP
Treatment with RJVA-002 resulted in a dose-dependent reduction in body weight - Fracty
Up to last close, stock down ~28% YTD

GUTS

Shares of drug developer Fractyl Healthrise 1.4% to $1.49 premarketCo says obesity gene therapy RJVA-002 showed ~30% weight loss in mice, in a preclinical trialThe therapy is designed to trigger the production of appetite-suppressing hormones, GLP-1 and GIPTreatment with RJVA-002 resulted in a dose-dependent reduction in body weight - FractyUp to last close, stock down ~28% YTD

BUZZ-Fractyl rises after obesity gene therapy shows promise in preclinical trial